HC Bioscience, Inc.

Terrific discussion on what it takes to develop an effective board with David Donabedian Longwood Fund, Nenad Grmusa DEM Biopharma, Inc., Tamar Thompson Alexion Pharmaceuticals, Inc., Leslie J Williams HC Bioscience, Inc. & Luba Greenwood, J.D. Dana-Farber Cancer Institute

Our team at HC Bioscience knows how to have some frightfully good fun! We brought our best Halloween spirit to the office. Nothing like a little costume competition and team bonding to kick off Halloween! Happy Halloween from all of us at HC Bio! 🧪💀🍬 #HalloweenAtWork #HCBio #TeamCulture #HalloweenFun #LifeAtHCBio #tRNA

Our CEO, Leslie J Williams has a passion for team building and fostering synergy.     On Tuesday, she’ll be speaking at the Longwood Healthcare Leaders Boston CEO event, on one of the most important and impactful teams to assemble—a Board of Directors.    We’re looking forward to Leslie’s insights from her session titled “Developing an Effective Board.” https://bit.ly/3Y8pgbF   #LongwoodHealthcareLeaders David Donabedian Nenad Grmusa Tamar Thompson Luba Greenwood, J.D.

This week, our CEO, Leslie J Williams, will be giving a talk at the #BIO Patient & Health Advocacy Summit in Washington D.C. Over the course of two days, patient advocacy organizations, policy thought leaders and master storytellers will unite around the promise of biotechnology.    Leslie will be speaking as part of the session titled "What’s in a Gene? The Future is Now" alongside Michele Oshman and Sulagna Bhattacharya. She'll share the latest on HC Bio’s universal therapeutic tRNA platform, which restores protein function, correcting the effect of nonsense mutations without altering DNA or mRNA.     Innovating for patients is at the core of HC Bio’s mission and we’re looking forward to sharing our science with the patient advocacy community!    Learn more here: https://bit.ly/3BVg3uB

We’re excited to highlight Cindy Driscoll, our Senior Vice President of Finance. Cindy has played an instrumental role in helping to shape our financial strategy and leading the growth of our finance and accounting teams. Her more than 20 years of industry experience have been essential in supporting preclinical development and allowing us to successfully advance our pioneering tRNA-based therapeutics. Cindy has an impressive background with previous roles at both public and private life sciences companies, where she successfully guided organizations from early-stage through IPO. Most recently, she served in senior positions at Magenta Therapeutics and Tokai Pharmaceuticals. We’re grateful to have Cindy as a part of the HC team!

The reauthorization of FDA’s Rare Pediatric Disease Priority Review voucher (PPRV) program has been making headlines as a critical path forward to ensuring continued innovation on behalf of rare pediatric disease patients.     Since launching in 2012, the program has awarded 53 vouchers for medicines to treat 39 rare pediatric diseases, benefiting more than 200,000 patients.    Recently, our CEO, Leslie J Williams, authored an article in the Boston Business Journal on the urgent need for congress to renew the program that addresses obstacles to progressing rare disease research.     Read Leslie’s timely perspective on the decision, which has now been delayed until December 20: https://bit.ly/3TOZu9W    #RareDisease

We’re thrilled to highlight Dr. Jose Lora, our Chief Scientific Officer! At HC, Dr. Lora leverages his extensive experience within translational research to lead the development of our cutting-edge tRNA-based therapies. Jose’s experience across multiple therapeutic areas and modalities— including autoimmunity, oncology, and rare disease as well as gene therapies, small molecules and proteins— provides him insight to advance our pipeline across multiple therapeutic areas including hemophilia, DMD, and cancer.   Jose is a distinguished scientist and biotech leader with an extensive background in translational research and therapeutic development. Prior to HC, he held roles as Chief Scientific Officer at Intergalactic Therapeutics and enGene, as well as senior roles at major companies such as Synlogic, Constellation Pharmaceuticals, GSK, Roche and Millennium Pharmaceuticals. We’re grateful to have him guiding our research and development efforts!

Each of our team members has taken a different, and sometimes winding path, into science, but we’re so glad that they’ve all made their way to HC!   When we welcomed Alex for his Make-A-Wish Day, HC Bio scientists participated in a round-table discussion with Alex and his family where they shared their backgrounds, what sparked their interest in science, and what they find most interesting about their current work. Alex and his brother shared their interest in planets and programming robots, and asked questions.

We recently welcomed the kids of HC Bio to our labs to help them learn about what their parents do every day. These junior scientists participated in a range of experiments that painted a picture of our innovative work on tRNA-based therapeutics. It was a fun-filled day, as we shared our passion for science with our children – perhaps they will enter this exciting field one day. The kids of HC are definitely ready for back-to-school season after this educational event!

We’re thrilled to announce that Simon Tsang, Ph.D., has joined our team as Chief Business Officer! Dr. Tsang brings a wealth of experience to his new role, including over two decades of industry experience and a proven track record in building innovation-focused companies and pipelines. Most recently, he served as an Operating Partner at Pivotal bioVenture Partners where he acted as Chief Business Officer to multiple biotech companies.     We’re excited to welcome Dr. Tsang and look forward to continuing to build a strong, skilled, and dedicated team.